Protai has built an end-to-end AI-based platform that comprehensively maps the course of disease on the protein level, enhancing the ability to observe cellular function and improve the way new drugs are discovered.

The company is building machine learning models combining deep proteomics to identify up to 1 million proteoforms, including post-translational modifications, protein-protein interactions, quantifications, and different structural populations of proteins.